Correlation Between 90331HPL1 and Entrada Therapeutics

Can any of the company-specific risk be diversified away by investing in both 90331HPL1 and Entrada Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining 90331HPL1 and Entrada Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between US BANK NATIONAL and Entrada Therapeutics, you can compare the effects of market volatilities on 90331HPL1 and Entrada Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in 90331HPL1 with a short position of Entrada Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of 90331HPL1 and Entrada Therapeutics.

Diversification Opportunities for 90331HPL1 and Entrada Therapeutics

0.07

Correlation Coefficient

90331HPL1  Entrada Therapeutics

Significant diversification

The 3 months correlation between 90331HPL1 and Entrada is 0.07. Overlapping area represents the amount of risk that can be diversified away by holding US BANK NATIONAL and Entrada Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Entrada Therapeutics and 90331HPL1 is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on US BANK NATIONAL are associated (or correlated) with Entrada Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Entrada Therapeutics has no effect on the direction of 90331HPL1 i.e., 90331HPL1 and Entrada Therapeutics go up and down completely randomly.

Pair Corralation between 90331HPL1 and Entrada Therapeutics

Assuming the 90 days trading horizon US BANK NATIONAL is expected to under-perform the Entrada Therapeutics. But the bond apears to be less risky and, when comparing its historical volatility, US BANK NATIONAL is 8.45 times less risky than Entrada Therapeutics. The bond trades about -0.02 of its potential returns per unit of risk. The Entrada Therapeutics is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest  1,509  in Entrada Therapeutics on September 24, 2024 and sell it today you would earn a total of  250.00  from holding Entrada Therapeutics or generate 16.57% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	66.27%
Values	Daily Returns

US BANK NATIONAL  vs.  Entrada Therapeutics

US BANK NATIONAL

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days US BANK NATIONAL has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, 90331HPL1 is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Entrada Therapeutics

Risk-Adjusted Performance

6 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Entrada Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating fundamental indicators, Entrada Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with 90331HPL1 and Entrada Therapeutics

The main advantage of trading using opposite 90331HPL1 and Entrada Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if 90331HPL1 position performs unexpectedly, Entrada Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entrada Therapeutics will offset losses from the drop in Entrada Therapeutics' long position.

The idea behind US BANK NATIONAL and Entrada Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.